DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Brian Snyder - 1 Scot Wolfe - 1 Salim Syed - 1 Sriparna Roy - 1 Krishna Chandra - 1
Top related locs:
Boston , Massachusetts U.S Bengaluru
Top related orgs:
Vertex Pharmaceuticals - 1 REUTERS - 1 CRISPR Therapeutics - 1 Staff - 1 U.S . Food - 1 Drug Administration - 1 UMass Chan Medical - 1 Analysts - 1

Search resuls for: "Salim Syed"


6 mentions found


☆ FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
  + stars: | 2023-10-31 | by ( ) www.reuters.com   time to read: +2 min
[1/2] A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder/File Photo Acquire Licensing RightsOct 31 (Reuters) - A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals (VRTX.O) and CRISPR Therapeutics (CRSP.BN) could assess potential safety risks of their sickle cell disease gene therapy after approval. If the therapy is approved, Vertex has proposed a 15-year follow up of patients to evaluate the safety outcomes of the therapy. Patients who were treated with the therapy were free from severe vaso-occlusive crisis for 12 months from the infusion of exa-cel. "It was made pretty clear that any theoretical off-target editing concerns do not outweigh the benefits of drug approval," said Salim Syed, analyst at Mizuho.
Persons: Brian Snyder, Scot Wolfe, Salim Syed, Sriparna Roy, Krishna Chandra Organizations: Vertex Pharmaceuticals, REUTERS, CRISPR Therapeutics, Staff, U.S . Food, Drug Administration, UMass Chan Medical, Analysts, FDA, Mizuho, Thomson Locations: Boston , Massachusetts, U.S, Bengaluru
☆ Eli Lilly has spent years and billions of dollars in search of an effective Alzheimer's drug. But success is not all or nothing for the stock
  + stars: | 2023-01-09 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +22 min
Eli Lilly (LLY) has spent decades researching Alzheimer's disease without successfully bringing to market a treatment that slows the memory-destroying condition. For Eli Lilly as a company, an Alzheimer's drug is an important pursuit. Lilly's Alzheimer's history Eli Lilly's "first real foray" into Alzheimer's came in the 1990s, according to Dr. John Sims, Eli Lilly's head of medical development for donanemab. Financial implications for Lilly LLY mountain 2021-10-08 The Club started a new position in Eli Lilly (LLY) in October 2021. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
☆ Watch CNBC's full interview with Mizuho's Salim Syed
  + stars: | 2022-12-12 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Mizuho's Salim SyedSalim Syed, Mizuho senior biotech analyst, joins 'Squawk on the Street' to discuss biotech M&A in general, the Amgen Horizon Therapeutics acquisition, and the balance sheet concerns associated with Amgen.
☆ Horizon Therapeutics' acquisition makes a "good strategic and financial sense" for Amgen, says Mizuho's Salim Syed
  + stars: | 2022-12-12 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHorizon Therapeutics' acquisition makes a "good strategic and financial sense" for Amgen, says Mizuho's Salim SyedSalim Syed, Mizuho senior biotech analyst, joins 'Squawk on the Street' to discuss biotech M&A in general, the Amgen Horizon Therapeutics acquisition, and the balance sheet concerns associated with Amgen.
☆ Roche's Alzheimer drug failing was a tailwind for a Biogen rally, Mizuho's Salim Syed
  + stars: | 2022-11-14 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRoche's Alzheimer drug failing was a tailwind for a Biogen rally, Mizuho's Salim SyedSalim Syed, Mizuho senior biotech analyst, joins 'Closing Bell' to discuss Biogen stock ticking up after Roche's new Alzheimer's drug didn't meet its goals.
☆ Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline
  + stars: | 2022-09-27 | by ( Deena Beasley Julie Steenhuysen | Deena Beasley | Julie Steenhuysen | ) www.reuters.com   time to read: +5 min
Shares of Biogen and Eisai were halted, but shares of Eli Lilly & Co , which is also developing an Alzheimer's drug, were up 6.7% in after hours trade. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. Symptomatic brain swelling was seen in 2.8% of those in the lecanemab group and none of the placebo group, they said. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost. Other plaque-targeting antibodies in late-stage development for Alzheimer's patients include Roche Holding AG's (ROG.S) gantenerumab and Eli Lilly's donanemab.
0 next >>
Total: 6